H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

FMCNA encourages dialysis patients to get vaccinated against flu

With early cases of seasonal flu already being reported in the U.S., Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is strongly encouraging dialysis patients to get flu shots to protect themselves against this common infectious disease.

9 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

University of Maryland receives renewed NIH funding for vaccine research

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has successfully competed for and received a renewed contract to conduct basic research and clinical studies of vaccines, diagnostics, and therapeutics. Support for this work to combat existing and emerging infectious diseases is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

27 Sep 2013

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU).

27 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

Researchers find reassuring evidence of H1N1 influenza vaccine's safety during pregnancy

Researchers from Boston University's Slone Epidemiology Center and UC San Diego, in collaboration with the American Academy of Allergy Asthma and Immunology, have found 'reassuring' evidence of the H1N1 influenza vaccine's safety during pregnancy.

24 Sep 2013

EcoHealth Alliance to study land use alteration in disease emergence, climate change in Asia

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, announced the award of a three-year, $2 million award to address land use alteration as a significant driver of both disease emergence and climate change in Asia.

24 Sep 2013

Researchers find evidence of H1N1 influenza vaccine's safety during pregnancy

Researchers from the University of California, San Diego School of Medicine and Boston University, in collaboration with the American Academy of Allergy Asthma and Immunology (AAAAI), have found evidence of the H1N1 influenza vaccine's safety during pregnancy.

24 Sep 2013

Research roundup: 'Cadillac' plan taxes; 'chronic care management' for substance abusers; long-term care services

As health coverage expands to tens of millions of Americans--through Medicaid expansion in states and the new state health insurance exchanges that will soon begin selling individual health coverage--some Americans with employer-sponsored health coverage are seeing their benefits decrease.

21 Sep 2013

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.

20 Sep 2013

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists at Saint Louis University are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China last spring, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health (NIH) to test vaccines to protect against the illness in adults.

20 Sep 2013

Scientists prepare to test vaccines to protect against new bird flu strain

Scientists at Group Health Research Institute are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China earlier this year, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health to test vaccines to protect against the illness in adults.

19 Sep 2013

Study: Rate of California ED visits higher among adult Medicaid beneficiaries

Emergency department (ED) use has been affected by insurance patterns over time and will likely be further affected by expansions of coverage from health care reform." Uninsured patients are often thought of as high and frequently inappropriate ED users, but insured patients, particularly those with Medicaid coverage, may have difficulties accessing primary care and may rely on EDs more frequently than uninsured patients, write Renee Y. Hsia, M.D., M.Sc., of the University of California, San Francisco, and colleagues.

18 Sep 2013

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.

10 Sep 2013

Scientists determine new strategy to estimate total viral diversity in mammals

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.

3 Sep 2013

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2).

27 Aug 2013

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.

22 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

H1N1 News and Research

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

FMCNA encourages dialysis patients to get vaccinated against flu

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

University of Maryland receives renewed NIH funding for vaccine research

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

Group Health helps protect public from infectious diseases through nationwide network

Researchers find reassuring evidence of H1N1 influenza vaccine's safety during pregnancy

EcoHealth Alliance to study land use alteration in disease emergence, climate change in Asia

Researchers find evidence of H1N1 influenza vaccine's safety during pregnancy

Research roundup: 'Cadillac' plan taxes; 'chronic care management' for substance abusers; long-term care services

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists prepare to test vaccines to protect against new bird flu strain

Study: Rate of California ED visits higher among adult Medicaid beneficiaries

Emerging H7N9 virus has potential to cause a pandemic

Scientists determine new strategy to estimate total viral diversity in mammals

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News